Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $48.20

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $48.20.

Several research firms have recently issued reports on OTLK. Chardan Capital restated a “buy” rating and set a $53.00 price objective on shares of Outlook Therapeutics in a report on Friday, August 16th. Ascendiant Capital Markets decreased their price objective on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Thursday, August 15th.

Institutional Trading of Outlook Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of OTLK. AQR Capital Management LLC bought a new position in shares of Outlook Therapeutics during the second quarter worth about $75,000. Squarepoint Ops LLC acquired a new position in Outlook Therapeutics in the second quarter worth approximately $232,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Outlook Therapeutics during the second quarter worth $303,000. LVW Advisors LLC acquired a new stake in Outlook Therapeutics during the 2nd quarter worth about $352,000. Finally, Rosalind Advisors Inc. raised its holdings in shares of Outlook Therapeutics by 44.3% during the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after acquiring an additional 138,225 shares during the period. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Trading Down 7.7 %

OTLK stock opened at $6.49 on Tuesday. The firm has a 50 day moving average of $7.70 and a 200-day moving average of $7.94. The company has a market cap of $151.90 million, a price-to-earnings ratio of -0.57 and a beta of 0.64. Outlook Therapeutics has a 12-month low of $4.09 and a 12-month high of $18.00.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.23. Sell-side analysts forecast that Outlook Therapeutics will post -3.65 earnings per share for the current fiscal year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.